Tag: USFDA Approved Immunotherapy 2024

Home / USFDA Approved Immunotherapy 2024

Categories

Retifanlimab-dlwr is approved by FDA for metastatic or recurrent locally advanced Merkel cell carcinoma

April 2023: Retifanlimab-dlwr (Zynyz, Incyte Corporation) received fast approval from the Food and Drug Administration to treat adult patients with metastatic or recurrent locally advanced Merkel cel...
usfda-approved-immunotherapy-2024

Scan the code